InvestorsHub Logo
Followers 52
Posts 3348
Boards Moderated 0
Alias Born 10/26/2013

Re: antihama post# 2249

Thursday, 07/12/2018 12:29:49 PM

Thursday, July 12, 2018 12:29:49 PM

Post# of 3283
JTO paper shows a 17% increase in EGFRex20in patients than we see from SPPIs Presentation slide 16 titled "NSCLC - Exon-20 Patient Population"!

SPPIs slide shows 9 to 11% (or 10%) of 16,300 patients (for the US) w EGFRex20in. That's 17% less than what the JTO abstract states (Note - the actual calc for the JTO abstract is 11.7% as opposed to the rounded # they state of 20%). Note these #s are just for EGFRex20in and they did not do the analysis for HER2ex20in.